Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for non-alcoholic fatty liver disease with liver function assessment
IRCT2016060628305N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of losartan in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Tehran University of Medical Sciences. Started Jul 2016; status: completed.
02
Drugs
losartan
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on IRCT2016060628305N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016060628305N1.